Sign In
Buy QNTM
$3.53
+0.220 (+6.65%)
At Close: Jul 13, 2026
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Monday, 12'th Jan 2026
New class action for Quantum Biopharma Ltd (QNTM) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 08'th Jan 2026
New class action for Quantum Biopharma Ltd (QNTM) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 01'st Jan 2026
New class action for Quantum Biopharma Ltd (QNTM) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 26'th Dec 2025
NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imp
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 25'th Dec 2025
New class action for Quantum Biopharma Ltd (QNTM) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026
Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial Studies Will Support Investigational New Drug Application (IND) with the US FDA, Incl
TORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has
TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has file
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has file
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
08:00pm, Wednesday, 10'th Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to
TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News' fl
Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
09:30am, Wednesday, 26'th Nov 2025
TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News' fl
TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News' fl
Quarter Shows Company's Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer Quarter Shows Company's Continued Str
Quantum BioPharma Ltd. Provides Corporate Update
07:51pm, Friday, 31'st Oct 2025
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portf
